Chardan Capital Issues Negative Forecast for TSHA Earnings

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) – Equities research analysts at Chardan Capital reduced their FY2025 earnings estimates for shares of Taysha Gene Therapies in a report released on Wednesday, November 5th. Chardan Capital analyst Y. Livshits now forecasts that the company will post earnings of ($0.35) per share for the year, down from their previous forecast of ($0.32). Chardan Capital has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Taysha Gene Therapies’ current full-year earnings is ($0.35) per share.

TSHA has been the subject of several other reports. Citizens Jmp raised their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “market outperform” rating in a research note on Wednesday, November 5th. Raymond James Financial began coverage on shares of Taysha Gene Therapies in a research note on Tuesday, October 21st. They set a “strong-buy” rating and a $13.00 price objective on the stock. Wells Fargo & Company raised their target price on shares of Taysha Gene Therapies from $7.50 to $8.00 and gave the company an “overweight” rating in a research note on Wednesday, August 13th. JMP Securities set a $8.00 price target on Taysha Gene Therapies in a research report on Wednesday, November 5th. Finally, Robert W. Baird raised their price objective on Taysha Gene Therapies from $7.00 to $12.00 and gave the company an “outperform” rating in a research report on Thursday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $9.70.

Taysha Gene Therapies Stock Up 1.6%

TSHA stock opened at $3.89 on Monday. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -11.79 and a beta of 1.00. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $5.51. The business has a 50 day moving average price of $4.01 and a two-hundred day moving average price of $3.10. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%.

Insider Activity

In other news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total transaction of $646,000.00. Following the transaction, the insider directly owned 1,006,439 shares of the company’s stock, valued at approximately $3,250,797.97. This trade represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.78% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds have recently added to or reduced their stakes in the stock. Nuveen LLC acquired a new stake in shares of Taysha Gene Therapies during the 1st quarter worth $760,000. Octagon Capital Advisors LP grew its stake in Taysha Gene Therapies by 2.4% during the first quarter. Octagon Capital Advisors LP now owns 10,700,000 shares of the company’s stock worth $14,873,000 after buying an additional 250,000 shares in the last quarter. ADAR1 Capital Management LLC grew its stake in Taysha Gene Therapies by 500.0% during the first quarter. ADAR1 Capital Management LLC now owns 1,066,309 shares of the company’s stock worth $1,482,000 after buying an additional 888,602 shares in the last quarter. XTX Topco Ltd bought a new position in Taysha Gene Therapies in the 1st quarter valued at about $282,000. Finally, Jefferies Financial Group Inc. acquired a new position in shares of Taysha Gene Therapies in the 1st quarter valued at approximately $341,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.